Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed

Joan B Soriano, Sarah J Lucas, Rupert Jones, Marc Miravitlles, Victoria Carter, Iain Small, David Price, Ravi Mahadeva

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

α1-antitrypsin deficiency (AATD) significantly increases the risk of developing chronic obstructive pulmonary disease (COPD), and testing of all COPD patients for AATD is recommended by the World Health Organization, European Respiratory Society and Global Initiative for Chronic Obstructive Lung Disease (GOLD). We aimed to determine trends for testing and diagnosing AATD from 1990 to 2014.This study analysed all patients diagnosed with COPD from about 550 UK Optimum Patient Care Research Database general practices, including a subgroup of those diagnosed before the age of 60 years.We identified 107 024 COPD individuals, of whom 29 596 (27.6 were diagnosed before 60 years of age. Of them, only 2.2% (95% CI 2.09textendash2.43 had any record of being tested for AATD. Of those tested, 23.7% (95% CI 20.5textendash27.1 were diagnosed with AATD. Between 1994 and 2013 the incidence of AATD diagnosis generally increased. A diagnosis of AATD was associated with being male, being an ex-smoker, more severe COPD with a lower forced expiratory volume in 1 s % pred and higher GOLD 2017 stages (all~plt;0.05).Despite an increase in the frequency of AATD testing since 1990, only 2.2% of patients diagnosed with COPD before the age of 60 years were tested. AATD prevalence was 23.7% in those tested. Thus, it appears that AATD remains markedly underdiagnosed in COPD patients.AATD remains markedly underdiagnosed in COPD patients and case-finding strategies for both conditions should be implemented http://ow.ly/wXK830k3RNf
Original languageEnglish
Article number1800360
JournalEuropean Respiratory Journal
Volume52
Issue number1
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Chronic Obstructive Pulmonary Disease
Forced Expiratory Volume
General Practice
Patient Care
Databases
Incidence
Research

Cite this

Soriano, J. B., Lucas, S. J., Jones, R., Miravitlles, M., Carter, V., Small, I., ... Mahadeva, R. (2018). Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed. European Respiratory Journal, 52(1), [1800360]. https://doi.org/10.1183/13993003.00360-2018

Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK : more testing is needed. / Soriano, Joan B; Lucas, Sarah J; Jones, Rupert; Miravitlles, Marc; Carter, Victoria; Small, Iain; Price, David; Mahadeva, Ravi.

In: European Respiratory Journal, Vol. 52, No. 1, 1800360, 07.2018.

Research output: Contribution to journalArticle

Soriano, JB, Lucas, SJ, Jones, R, Miravitlles, M, Carter, V, Small, I, Price, D & Mahadeva, R 2018, 'Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed', European Respiratory Journal, vol. 52, no. 1, 1800360. https://doi.org/10.1183/13993003.00360-2018
Soriano, Joan B ; Lucas, Sarah J ; Jones, Rupert ; Miravitlles, Marc ; Carter, Victoria ; Small, Iain ; Price, David ; Mahadeva, Ravi. / Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK : more testing is needed. In: European Respiratory Journal. 2018 ; Vol. 52, No. 1.
@article{8186e626e25a4ed6a175b88f4c136503,
title = "Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed",
abstract = "α1-antitrypsin deficiency (AATD) significantly increases the risk of developing chronic obstructive pulmonary disease (COPD), and testing of all COPD patients for AATD is recommended by the World Health Organization, European Respiratory Society and Global Initiative for Chronic Obstructive Lung Disease (GOLD). We aimed to determine trends for testing and diagnosing AATD from 1990 to 2014.This study analysed all patients diagnosed with COPD from about 550 UK Optimum Patient Care Research Database general practices, including a subgroup of those diagnosed before the age of 60 years.We identified 107 024 COPD individuals, of whom 29 596 (27.6 were diagnosed before 60 years of age. Of them, only 2.2{\%} (95{\%} CI 2.09textendash2.43 had any record of being tested for AATD. Of those tested, 23.7{\%} (95{\%} CI 20.5textendash27.1 were diagnosed with AATD. Between 1994 and 2013 the incidence of AATD diagnosis generally increased. A diagnosis of AATD was associated with being male, being an ex-smoker, more severe COPD with a lower forced expiratory volume in 1 s {\%} pred and higher GOLD 2017 stages (all~plt;0.05).Despite an increase in the frequency of AATD testing since 1990, only 2.2{\%} of patients diagnosed with COPD before the age of 60 years were tested. AATD prevalence was 23.7{\%} in those tested. Thus, it appears that AATD remains markedly underdiagnosed in COPD patients.AATD remains markedly underdiagnosed in COPD patients and case-finding strategies for both conditions should be implemented http://ow.ly/wXK830k3RNf",
author = "Soriano, {Joan B} and Lucas, {Sarah J} and Rupert Jones and Marc Miravitlles and Victoria Carter and Iain Small and David Price and Ravi Mahadeva",
note = "Support statement: Optimum Patient Care Research Database and Respiratory Effectiveness Group. R. Jones was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula (NIHR CLAHRC South West Peninsula). Funding information for this article has been deposited with the Crossref Funder Registry.",
year = "2018",
month = "7",
doi = "10.1183/13993003.00360-2018",
language = "English",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK

T2 - more testing is needed

AU - Soriano, Joan B

AU - Lucas, Sarah J

AU - Jones, Rupert

AU - Miravitlles, Marc

AU - Carter, Victoria

AU - Small, Iain

AU - Price, David

AU - Mahadeva, Ravi

N1 - Support statement: Optimum Patient Care Research Database and Respiratory Effectiveness Group. R. Jones was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula (NIHR CLAHRC South West Peninsula). Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2018/7

Y1 - 2018/7

N2 - α1-antitrypsin deficiency (AATD) significantly increases the risk of developing chronic obstructive pulmonary disease (COPD), and testing of all COPD patients for AATD is recommended by the World Health Organization, European Respiratory Society and Global Initiative for Chronic Obstructive Lung Disease (GOLD). We aimed to determine trends for testing and diagnosing AATD from 1990 to 2014.This study analysed all patients diagnosed with COPD from about 550 UK Optimum Patient Care Research Database general practices, including a subgroup of those diagnosed before the age of 60 years.We identified 107 024 COPD individuals, of whom 29 596 (27.6 were diagnosed before 60 years of age. Of them, only 2.2% (95% CI 2.09textendash2.43 had any record of being tested for AATD. Of those tested, 23.7% (95% CI 20.5textendash27.1 were diagnosed with AATD. Between 1994 and 2013 the incidence of AATD diagnosis generally increased. A diagnosis of AATD was associated with being male, being an ex-smoker, more severe COPD with a lower forced expiratory volume in 1 s % pred and higher GOLD 2017 stages (all~plt;0.05).Despite an increase in the frequency of AATD testing since 1990, only 2.2% of patients diagnosed with COPD before the age of 60 years were tested. AATD prevalence was 23.7% in those tested. Thus, it appears that AATD remains markedly underdiagnosed in COPD patients.AATD remains markedly underdiagnosed in COPD patients and case-finding strategies for both conditions should be implemented http://ow.ly/wXK830k3RNf

AB - α1-antitrypsin deficiency (AATD) significantly increases the risk of developing chronic obstructive pulmonary disease (COPD), and testing of all COPD patients for AATD is recommended by the World Health Organization, European Respiratory Society and Global Initiative for Chronic Obstructive Lung Disease (GOLD). We aimed to determine trends for testing and diagnosing AATD from 1990 to 2014.This study analysed all patients diagnosed with COPD from about 550 UK Optimum Patient Care Research Database general practices, including a subgroup of those diagnosed before the age of 60 years.We identified 107 024 COPD individuals, of whom 29 596 (27.6 were diagnosed before 60 years of age. Of them, only 2.2% (95% CI 2.09textendash2.43 had any record of being tested for AATD. Of those tested, 23.7% (95% CI 20.5textendash27.1 were diagnosed with AATD. Between 1994 and 2013 the incidence of AATD diagnosis generally increased. A diagnosis of AATD was associated with being male, being an ex-smoker, more severe COPD with a lower forced expiratory volume in 1 s % pred and higher GOLD 2017 stages (all~plt;0.05).Despite an increase in the frequency of AATD testing since 1990, only 2.2% of patients diagnosed with COPD before the age of 60 years were tested. AATD prevalence was 23.7% in those tested. Thus, it appears that AATD remains markedly underdiagnosed in COPD patients.AATD remains markedly underdiagnosed in COPD patients and case-finding strategies for both conditions should be implemented http://ow.ly/wXK830k3RNf

U2 - 10.1183/13993003.00360-2018

DO - 10.1183/13993003.00360-2018

M3 - Article

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

M1 - 1800360

ER -